Navigation Links
Ardea Biosciences to Present Preclinical Data on Three HIV Non-Nucleoside Reverse Transcriptase Inhibitors During 15th Annual Conference on Retroviruses and Opportunistic Infections
Date:1/29/2008

- Activity data on lead NNRTI, RDEA806, and next generation compounds to be

discussed -

CARLSBAD, Calif., Jan. 29 /PRNewswire-FirstCall/ -- Ardea Biosciences, Inc. (Nasdaq: RDEA) today announced that preclinical data on the Company's non-nucleoside reverse transcriptase inhibitor (NNRTI) family of compounds, including RDEA806, RDEA427 and RDEA640, will be presented during the 15th Annual Conference on Retroviruses and Opportunistic Infections (CROI) in Boston, February 3-6, 2008.

The presentation details are as follows:

Date/Time: Tuesday, February 5, 2008, 1:00 p.m. Eastern Standard Time

Title: An IQ Assessment of RDEA806, A Potent NNRTI with an Excellent

Activity Profile in the Presence of Human Serum Proteins

Location: Poster Session 123 (Poster # 731) -- Hall A, Hynes Convention

Center

Date/Time: Tuesday, February 5, 2008, 1:00 p.m. Eastern Standard Time

Title: RDEA427 and RDEA640 are Novel NNRTIs with Potent Anti-HIV Activity

against NNRTI-Resistance Viruses

Location: Poster Session 123 (Poster # 730) -- Hall A, Hynes Convention

Center

About RDEA806

RDEA806 is a novel non-nucleoside reverse transcriptase inhibitor (NNRTI) for the potential treatment of HIV infection. Based on preclinical and clinical studies to-date, Ardea believes that RDEA806 possesses several attractive properties. These include: potential for potent antiviral activity against a wide range of HIV viral isolates, including those that are resistant to efavirenz (Sustiva(R)), Bristol-Myers Squibb) and other currently available NNRTIs; a high genetic barrier to resistance; the potential to be administered in a
'/>"/>

SOURCE Ardea Biosciences, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Ardea Biosciences Announces $40 Million Private Placement
2. Ardea Biosciences to Participate in RBC Capital Markets 2007 Healthcare Conference
3. Ardea Biosciences, Inc. Reports Third Quarter 2007 Operating and Financial Results
4. Ardea Biosciences Announces Changes to Research Management
5. Selection of Development Candidate Triggers $0.5 Million Milestone Payment to Ardea Biosciences, Inc.
6. Profectus BioSciences Inc. Names Shawn Patrick OBrien CEO
7. Study Shows Coronado Biosciences Bcl-2 Inhibitor, Apogossypol, is More Efficacious, Less Toxic than Gossypol in Animal Models
8. Neurocrine Biosciences Announces Conference Call and Webcast to Present Fourth Quarter and Year End 2007 Financial Results
9. YM BioSciences provides update on AeroLEF(TM) clinical development program
10. DuPont Names Nicholas Fanandakis as Group Vice President - DuPont Applied BioSciences
11. YM BIOSCIENCES ANNOUNCES NIMOTUZUMAB COLORECTAL CANCER TRIAL FIRST COHORT IS CLOSED TO ACCRUAL
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/30/2014)... Mass. , July 30, 2014  Decision ... pharmacy and medical directors in the ... drivers of biosimilar market penetration will be the ... organizations (MCOs) and the expected lower cost to ... for biosimilars that meet their pricing expectations in ...
(Date:7/30/2014)... 30, 2014 While administrative claims ... services research for a relatively long period of ... regarding the use of these ‘big data’ for ... By combining today’s powerful computer technology with the ... ‘big data’ holds significant promise for identifying optimal ...
(Date:7/30/2014)... July 30, 2014 With the ... of personal health expenditure as well as the ... system, China diagnostic reagent industry has been developing ... 90%. In 2013, Chinese in vitro diagnostics market ... came from in vitro diagnostic reagents. , ...
(Date:7/30/2014)... (PRWEB) July 30, 2014 Yuma ... facility and complementary therapies brings comprehensive cancer care ... state-of-the-art Yuma Regional Cancer Center has officially opened. ... the program includes services such as open, semi-private ... therapy, American Cancer Society Resource Center, hematology, rehabilitation ...
Breaking Biology Technology:Surveyed U.S. Payers Expect Cost Savings to MCOs and Patients to be the Strongest Drivers of Biosimilar Uptake 2Surveyed U.S. Payers Expect Cost Savings to MCOs and Patients to be the Strongest Drivers of Biosimilar Uptake 3Leveraging ‘Big Data’ - Methodological Considerations in Health Services Research, New Webinar Hosted by Xtalks 2China Diagnostic Reagent Industry Report, 2013-2016 | Researchmoz 2China Diagnostic Reagent Industry Report, 2013-2016 | Researchmoz 3Sate-of-the-Art Yuma Regional Cancer Center Officially Opens 2
... Pasteuria Bioscience announced that it has received registration ... Pasteuria usgae . This is a critical step towards ... bacteria prevalent in soil that have long been recognized as ... , "We,re very pleased to receive this EPA registration," ...
... STOCKHOLM, June 8 Diamyd Medical reported today,that the company ... to include children with type 1 diabetes from 10 years,of ... vaccine Diamyd(R). , (Logo: http://www.newscom.com/cgi-bin/prnh/20080314/297194 ... conducting two parallel phase III studies, one in,Europe and one ...
... Through One Year , , HERZLIYA, Israel and SKILLMAN, ... U.S. Food and Drug Administration (FDA) approved a labeling supplement ... EVOLENCE(R), a collagen-based dermal filler for the correction of moderate ... , , To view the Multimedia News Release, go ...
Cached Biology Technology:Pasteuria Bioscience Receives EPA Registration for Nematode Control 2Diamyd(R) Phase III Study Approved for Younger Patients in the US 2Photos: FDA Approves 12-Month Labeling Update for EVOLENCE(R) Collagen-Based Facial Filler 2Photos: FDA Approves 12-Month Labeling Update for EVOLENCE(R) Collagen-Based Facial Filler 3Photos: FDA Approves 12-Month Labeling Update for EVOLENCE(R) Collagen-Based Facial Filler 4
(Date:7/30/2014)... scientists unveiled the first high-resolution map of the ... country of Per. The new and improved methodology ... change for future market-based carbon economies. The ... ecological diversity and it provides the critical input ... conservation, land use, and enforcement purposes. The technique ...
(Date:7/29/2014)... of Bristol,s Nutrition and Behaviour Unit (NBU) has looked ... planning meals. , The research, to be presented at ... (SSIB 2014) in Seattle, USA this week [29 July ... team was led by Professor Jeff Brunstrom, and is ... part of a Biotechnology and Biological Sciences Research Council ...
(Date:7/29/2014)... the climate warms and sea ice retreats, the North ... of increasingly open water which is predicted to extend ... this century. Storms thus have the potential to create ... new and unpredictable element to the region. , A University ... in the middle of the Arctic Ocean, and detected ...
Breaking Biology News(10 mins):Peru's carbon quantified: Economic and conservation boon 2Peru's carbon quantified: Economic and conservation boon 3Huge waves measured for first time in Arctic Ocean 2Huge waves measured for first time in Arctic Ocean 3
... engineers at Purdue University have developed a new method ... and they are proposing the creation of mobile processing ... fuels. "What,s important is that you can ... chips, switch grass, corn stover, rice husks, wheat straw ...
... tract is a teeming mass of hundreds of types of ... help us digest food and keep bad bacteria in check. ... receptor is a key player amid the gut bacteria ... helping to govern their activity, responding to their cues, and ...
... calling on policymakers to encourage the transition from coal-based electricity ... carbon tax. Such a mechanism would help limit carbon ... Change Conference in Copenhagen last December, the United States pledged ... by 17 percent by 2020. Dagobert Brito, the ...
Cached Biology News:New biofuels processing method for mobile facilities 2New biofuels processing method for mobile facilities 3Amid the murk of 'gut flora,' vitamin D receptor emerges as a key player 2Amid the murk of 'gut flora,' vitamin D receptor emerges as a key player 3Researchers calculate the cost of CO2 emissions, call for carbon tax 2
... (1995) This volume provides excellent ... for the study of major HIV proteins ... ribonuclease H, integrase and protease. Expression of ... Tat and Rev assays; HIV/CD4 interactions; transient ...
Monkey IL-2 ELISPOT Kit with white/opague microtiter plates...
Tachykinin (H-2)...
Human GATA-2 Affinity Purified Polyclonal Ab...
Biology Products: